Jazi Sayed Mohammad Hashemi, Shirvani Hsan, Mansouri Asieh, Kermani-Alghoraishi Mohammad, Bordbar Armin, Sattar Fereshteh, Safaei Ali, Farshidi Hossein, Assareh Ahmad Reza, Kazemi Toba, Khosravi Alireza
School of Medicine, Department of Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler. 2024 Jan-Feb;20(1):20-30. doi: 10.48305/arya.2024.11893.0.
The National Persian Registry of Cardiovascular Disease (N-PROVE) has been established to provide a comprehensive database of cardiovascular diseases in the Iranian community for further investigations and to develop national guidelines for the diagnosis, treatment, and prevention of cardiovascular disease (CVD). As with most clinical registries, a quality control audit is necessary to ensure a comprehensive and accurate registry; the current study aims to assess the validity and quality of the N-PROVE/Angiography/Percutaneous Coronary Intervention (PCI) registry.
The current cross-sectional quality assessment study serves as an example of data quality assessment in N-PROVE on a sample of patients registered in the N-PROVE/Angiography/PCI registry since 2020. Accordingly, data of 194 patients, including comorbidities, angiography, and angioplasty characteristics, were collected from the N-PROVE/Angiography/PCI registry as the main database and reevaluated by a panel consisting of a cardiologist and two coronary intervention fellowships as a test database.
The quality control of the population-based healthcare database, the N-PROVE/PCI, revealed that the average error rate in terms of comorbidities, angiography characteristics, angioplasty characteristics, and in total were 3.8%, 2.3%, 3%, and 3.03%, respectively.
According to the findings of this study, the N-PROVE/PCI registry had an average error of less than 4% in the assessed dimensions, including comorbidities, angiography, and angioplasty characteristics. Therefore, this registry appears valid and may be used for contemporary epidemiological studies.
伊朗心血管疾病国家注册库（N-PROVE）已建立，旨在为伊朗社区提供心血管疾病的综合数据库，以进行进一步研究，并制定心血管疾病（CVD）诊断、治疗和预防的国家指南。与大多数临床注册库一样，进行质量控制审核对于确保注册库全面准确很有必要；本研究旨在评估N-PROVE/血管造影/经皮冠状动脉介入治疗（PCI）注册库的有效性和质量。
当前的横断面质量评估研究是对自2020年以来在N-PROVE/血管造影/PCI注册库中登记的患者样本进行N-PROVE数据质量评估的一个实例。因此，从N-PROVE/血管造影/PCI注册库这个主要数据库中收集了194例患者的数据，包括合并症、血管造影和血管成形术特征，并由一名心脏病专家和两名冠状动脉介入研究员组成的小组作为测试数据库进行重新评估。
基于人群的医疗保健数据库N-PROVE/PCI的质量控制显示，合并症、血管造影特征、血管成形术特征以及总体的平均错误率分别为3.8%、2.3%、3%和3.03%。
根据本研究结果，N-PROVE/PCI注册库在合并症、血管造影和血管成形术特征等评估维度上的平均错误率低于4%。因此，该注册库似乎是有效的，可用于当代流行病学研究。
